Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity

Stephanie K. Dougan, Michael Dougan, Jun Kim, Jacob A. Turner, Souichi Ogata, Hyun Il Cho, Rudolf Jaenisch, Esteban Celis, Hidde L. Ploegh

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN) mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ greatly in their affinity for antigen (TRP1(high) or TRP1(low)) as inferred from tetramer dissociation and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1(high) or TRP1(low) mice show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous B16 melanoma. Although naïve TRP1(low) CD8 T cells do not affect tumor growth, upon activation these cells function indistinguishably from TRP1(high) cells in vivo, limiting tumor cell growth and increasing mouse survival. The anti-tumor effect of both TRP1(high) and TRP1(low) CD8 T cells is enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes of T cells conferred by TCR affinity, and they may serve as a platform for screening immunomodulatory cancer therapies.

Original languageEnglish (US)
Pages (from-to)99-111
Number of pages13
JournalCancer Immunology Research
Issue number2
StatePublished - Aug 1 2013


  • B16
  • T cell receptor
  • melanoma
  • somatic cell nuclear transfer
  • tyrosinase related protein 1

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity'. Together they form a unique fingerprint.

Cite this